AMGN · News · 20260804N
Product Pipeline Progress
AMGEN INC · 2026-08-04 · Importance 28 · Surprise 42 · In source text
Amgen is continuing late-stage development of MariTide, its investigational obesity treatment, including the Phase 3 MARITIME-1-EXTENSION study evaluating long-term weight-loss maintenance and tolerability. The company is also advancing Phase 3 programs for key growth drivers and expects future catalysts from MariTide and olpasiran. Amgen discontinued early development of AMG 513, an obesity candidate in a Phase 1 study, while maintaining its broader focus on the obesity market. Pipeline expansion is being supported by increased investment in late-stage clinical programs.
Key facts
- Amgen said it will halt development of AMG 513, its early-stage obesity treatment that was in a Phase 1 study. source
- Amgen ended early development of its experimental obesity drug candidate AMG 513. source
- Amgen reported it was ending early development of an obesity treatment while continuing other obesity program development, as noted across multiple reports. source
- Amgen disclosed that it ended early development of AMG 513 and did not provide a reason for discontinuation (WSJ report). source
- Amgen is continuing development of another weight-loss drug, MariTide (maridebart cafraglutide/AMG 133), and extended the Phase 3 MARITIME-1-EXTENSION study. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | contingent | — | Amgen said it will halt development of AMG 513, its early-stage obesity treatment that was in a Phase 1 study. |
| operating_income | positive | committed | — | Amgen said it will halt development of AMG 513, its early-stage obesity treatment that was in a Phase 1 study. |